Valuation Metrics: A Closer Look at Amanta Healthcare
As of 24 August 2026, Amanta Healthcare’s P/E ratio stands at 47.18, a figure that has contributed to its reclassification from an attractive to a fair valuation grade. This P/E is elevated compared to several peers but remains below some of the more expensive names in the sector. For instance, Fredun Pharma trades at a P/E of 54.82, while Shukra Pharma’s P/E is even higher at 57.05. Conversely, Venus Remedies and Syncom Formulations present more modest valuations with P/Es of 19.91 and 17.83 respectively.
The company’s price-to-book value ratio of 3.44 also signals a premium over book value, though it is not the highest in the peer group. This metric suggests that investors are willing to pay a significant premium for Amanta’s net assets, reflecting confidence in its growth prospects and asset utilisation.
Other valuation multiples such as EV to EBIT (22.35) and EV to EBITDA (15.30) further illustrate the company’s standing within the sector. While these multiples are elevated, they are comparatively moderate when juxtaposed with peers like Ind-Swift Laboratories, which exhibits an EV to EBITDA of 41.27, indicating a much higher valuation premium.
Comparative Sector Analysis
Within the Pharmaceuticals & Biotechnology sector, valuation grades vary widely. Amanta Healthcare’s current “fair” valuation contrasts with several peers rated as “very expensive,” including Ind-Swift Labs, Hester Biosciences, and Jagsonpal Pharmaceuticals. Meanwhile, companies such as TTK Healthcare maintain an “attractive” valuation grade, supported by a lower P/E of 20.36 and a higher PEG ratio of 1.43, suggesting more favourable growth-adjusted valuations.
Amanta’s PEG ratio remains at zero, which may indicate either a lack of consensus on growth projections or a data anomaly. This contrasts with peers whose PEG ratios range from 0.13 to 2.47, reflecting varying growth expectations and valuation premiums.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Financial Performance and Returns Contextualised
Amanta Healthcare’s recent stock price performance has been impressive, with the current price at ₹195.35, marking a 5.00% gain on the day and reaching its 52-week high. The stock has delivered a remarkable 1-week return of 24.74% and a 1-month return of 15.97%, significantly outperforming the Sensex, which declined by 0.60% and rose marginally by 0.09% over the same periods respectively.
Year-to-date, Amanta’s stock has surged by 79.71%, while the Sensex has fallen by 9.01%. This outperformance highlights strong investor interest despite the shift in valuation grading. The company’s return on capital employed (ROCE) of 11.06% and return on equity (ROE) of 7.30% indicate moderate efficiency in generating returns, though these figures are not exceptional within the sector.
Micro-Cap Status and Market Capitalisation
Amanta Healthcare is classified as a micro-cap stock, which inherently carries higher volatility and risk compared to larger peers. This status is reflected in its Mojo Score of 40.0 and a recent downgrade from a Hold to a Sell grade on 3 August 2026. The downgrade signals caution from analysts, likely influenced by the stretched valuation multiples and the company’s financial metrics relative to sector benchmarks.
Investors should weigh the company’s strong recent price momentum against these valuation concerns and the inherent risks of micro-cap stocks in the Pharmaceuticals & Biotechnology sector.
Why settle for Amanta Healthcare Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Valuation Shifts: Implications for Investors
The transition of Amanta Healthcare’s valuation grade from attractive to fair reflects a recalibration of investor expectations. While the company’s P/E ratio remains elevated relative to some peers, it is not the most expensive in the sector, suggesting that the market is pricing in growth potential but with increased caution.
Investors should consider the company’s strong recent returns and sector positioning against the backdrop of its micro-cap status and moderate profitability metrics. The fair valuation grade implies that while the stock may no longer offer the same margin of safety as before, it still holds potential for investors with a higher risk tolerance and a long-term horizon.
Comparisons with peers reveal that Amanta Healthcare is positioned between very expensive and attractive valuations, making it a middle-ground option for investors seeking exposure to Pharmaceuticals & Biotechnology micro-caps.
Conclusion
Amanta Healthcare Ltd’s valuation adjustment from attractive to fair is a significant development for investors analysing the Pharmaceuticals & Biotechnology sector. The company’s elevated P/E and P/BV ratios, combined with strong recent price performance, suggest a market that is optimistic yet cautious. Given the micro-cap classification and recent downgrade to a Sell grade, investors should carefully assess their risk appetite and investment horizon before committing capital.
Ultimately, Amanta Healthcare remains a noteworthy player in its sector, but its valuation shift signals the need for a more nuanced approach to investment decisions, balancing growth prospects with valuation discipline.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
